We are live on ! Find out more
BVF Inc

BVF Inc Portfolio holdings

AUM $3.04B Turnover 10.42%
1-Year Est. Return 129.63%
This Fund
S&P 500
This Quarter Est. Return
+4.92%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$515M
AUM Growth
–
Cap. Flow
+$483M
Cap. Flow %
93.73%
Top 10 Hldgs %
87.64%
Holding
24
New
22
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 88%
2 Miscellaneous 12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
LGND icon
1
Ligand Pharmaceuticals
LGND
$5.9B
$136M 26.3%
+5,805,529
New +$104M
2013 Q2
0 quarters
CCXI icon
2
DELISTED
ChemoCentryx
CCXI
$71.1M 13.79%
+5,026,766
New +$65.1M
2013 Q2
0 quarters
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$800M
$52.3M 10.14%
+6,271,558
New +$76M
2013 Q2
0 quarters
ARRY icon
4
DELISTED
Array Biopharma
ARRY
$50.5M 9.81%
+11,131,858
New +$59.9M
2013 Q2
0 quarters
RIGL icon
5
Rigel Pharmaceuticals
RIGL
$799M
$32.5M 6.31%
+973,070
New +$44.1M
2013 Q2
0 quarters
GYRE icon
6
Gyre Therapeutics
GYRE
$484M
$26.4M 5.11%
+7,837
New +$29.8M
2013 Q2
0 quarters
CYTK icon
7
Cytokinetics
CYTK
$7.22B
$19.9M 3.86%
+1,718,905
New +$13.5M
2013 Q2
0 quarters
CASC
8
DELISTED
Cascadian Therapeutics
CASC
$12.6M 2.45%
+1,348,880
New +$17.3M
2013 Q2
0 quarters
EXEL icon
9
Exelixis
EXEL
$16.5B
$11.4M 2.2%
+2,502,256
New +$11.9M
2013 Q2
0 quarters
QLTI icon
10
DELISTED
QLT Inc
QLTI
$10.4M 2.02%
+2,370,263
New +$19.1M
2013 Q2
0 quarters
PTLA
11
DELISTED
Portola Pharmaceuticals
PTLA
$7.51M 1.46%
+305,786
New +$6.08M
2013 Q2
0 quarters
RCPT
12
DELISTED
Receptos
RCPT
$6.36M 1.24%
+320,000
New +$5.4M
2013 Q2
0 quarters
ARQL
13
DELISTED
Arqule
ARQL
$6.11M 1.19%
+2,632,432
New +$7.09M
2013 Q2
0 quarters
FLNA icon
14
Filana Therapeutics
FLNA
$24.1M
$5.21M 1.01%
+336,761
New +$7.12M
2013 Q2
0 quarters
AVNR
15
DELISTED
Avanir Pharmaceuticals
AVNR
$4.63M 0.9%
+1,006,053
New +$3.46M
2013 Q2
0 quarters
PTN icon
16
Palatin Technologies
PTN
$10M
$3.12M 0.61%
+4,160
New +$3.19M
2013 Q2
0 quarters
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$268M
$2.72M 0.53%
+153,500
New +$2.99M
2013 Q2
0 quarters
RGLS icon
18
DELISTED
Regulus Therapeutics
RGLS
$2.61M 0.51%
+2,220
New +$2.11M
2013 Q2
0 quarters
ANTH
19
DELISTED
Anthera Pharmaceuticals
ANTH
$2.07M 0.4%
+69,953
New +$2.61M
2013 Q2
0 quarters
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
$931K 0.18%
+151,406
New +$782K
2013 Q2
0 quarters
PRTK
21
DELISTED
Paratek Pharmaceuticals
PRTK
$453K 0.09%
+12,500
New +$536K
2013 Q2
0 quarters
GNVC
22
DELISTED
GenVec
GNVC
$180K 0.03%
+48,610
New +$410K
2013 Q2
0 quarters

Similar funds

BVF Inc's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for BVF Inc, which disclosed 24 positions worth $515M. Its ten largest holdings account for 88% of the portfolio.

Its largest position is Ligand Pharmaceuticals: 5,805,529 shares worth $136M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, followed by Miscellaneous.

  • BVF Inc's largest Q2 2013 buy was Ligand Pharmaceuticals: 5,805,529 shares worth $136M.
  • BVF Inc's ten largest holdings make up 88% of its $515M portfolio in Q2 2013.
  • BVF Inc disclosed 24 positions in Q2 2013, its first 13F filing on record.

Based on BVF Inc's 13F filing for Q2 2013, filed 14 Aug 2013.